<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Ambien CR,ATC code,Ambien,Barbiturates,Benzodiazepines,Bioavailability,CAS number,Chemical formula,Elimination half-life,Excretion,Food and Drug Administration" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Ambien CR - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Ambien CR</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <table border="1" cellpadding="3" cellspacing="0" width="250px" align="right" style="border-collapse: collapse; margin: 0 0 0 0.5em">
<tr>
<td bgcolor="#FFFFFF" align="center" colspan="2">
<p><a href="../../../z/o/l/Image%7EZolpidem.png_5875.html" class="image" title="Zolpidem chemical structure"><img src="../../../upload/thumb/8/83/Zolpidem.png/200px-Zolpidem.png" alt="Zolpidem chemical structure" width="200" height="123" longdesc="../../../z/o/l/Image%7EZolpidem.png_5875.html" /></a><br />
<i>Zolpidem Tartrate</i></p>
</td>
</tr>
<tr>
<td align="center" colspan="2">N,N,<i>6-trimethyl-2-(4-methylphenyl)-<br />
imidazo(1,2-a)pyridine-3-acetamide</i></td>
</tr>
<tr align="center" style="border-bottom: 3px solid gray">
<td><b><a href="../../../c/a/s/CAS_number_b7cb.html" title="CAS number">CAS number</a></b><br />
not known</td>
<td><b><a href="../../../a/t/c/ATC_code_3c84.html" title="ATC code">ATC code</a></b><br />
not known</td>
</tr>
<tr>
<td bgcolor="#EEEEEE"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Chemical formula</a></td>
<td bgcolor="#DDEEFF">C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O</td>
</tr>
<tr>
<td bgcolor="#EEEEEE"><a href="../../../m/o/l/Molecular_weight.html" title="Molecular weight">Molecular weight</a></td>
<td bgcolor="#DDEEFF">764.88</td>
</tr>
<tr>
<td bgcolor="#EEEEEE"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#DDEEFF">92% bound in plasma</td>
</tr>
<tr>
<td bgcolor="#EEEEEE">Metabolism</td>
<td bgcolor="#DDEEFF">Hepatic</td>
</tr>
<tr>
<td bgcolor="#EEEEEE"><a href="../../../e/l/i/Elimination_half-life.html" title="Elimination half-life">Elimination half-life</a></td>
<td bgcolor="#DDEEFF">2.8 hours (normal liver function)</td>
</tr>
<tr>
<td bgcolor="#EEEEEE"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#DDEEFF">Renal</td>
</tr>
<tr>
<td bgcolor="#EEEEEE"><a href="../../../p/r/e/Pregnancy_category_%28pharmaceutical%29.html" title="Pregnancy category (pharmaceutical)">Pregnancy category</a></td>
<td bgcolor="#DDEEFF">Category B</td>
</tr>
<tr>
<td bgcolor="#EEEEEE"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#DDEEFF">Schedule IV</td>
</tr>
<tr>
<td bgcolor="#EEEEEE">Routes of administration</td>
<td bgcolor="#DDEEFF">Oral</td>
</tr>
<tr>
<td bgcolor="#EEEEEE">Formulation(s)</td>
<td bgcolor="#DDEEFF">Ambien CR: 6.25mg tablet, 12.5mg tablet</td>
</tr>
</table>
<p><b>Ambien CR</b> is different from <a href="../../../a/m/b/Ambien.html" title="Ambien">Ambien</a> in that it uses <a href="../../../z/o/l/Zolpidem.html" title="Zolpidem">zolpidem</a> tartrate extended release. The continued release allows for increased effectiveness of a lower, consistent dose of zolpidem, gives less or no <a href="../../../h/a/n/Hangover.html" title="Hangover">hangover</a>, and is proven to be more effective than traditional <a href="../../../a/m/b/Ambien.html" title="Ambien">Ambien</a> in quality of <a href="../../../s/l/e/Sleep.html" title="Sleep">sleep</a> (less/no sleep interruptions) and depth of <a href="../../../s/l/e/Sleep.html" title="Sleep">sleep</a> (preserves stage 3 and 4 deep <a href="../../../s/l/e/Sleep.html" title="Sleep">sleep</a>.) Ambien CR is also celebrated because it lacks many of the <a href="../../../z/o/l/Zolpidem.html#Side-effects" title="Zolpidem">side effects</a> for which non-CR Ambien is particularly notorious.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Uses"><span class="tocnumber">1</span> <span class="toctext">Uses</span></a></li>
<li class="toclevel-1"><a href="#Pharmacodynamics"><span class="tocnumber">2</span> <span class="toctext">Pharmacodynamics</span></a></li>
<li class="toclevel-1"><a href="#Pharmacokinetics"><span class="tocnumber">3</span> <span class="toctext">Pharmacokinetics</span></a></li>
<li class="toclevel-1"><a href="#Absorption"><span class="tocnumber">4</span> <span class="toctext">Absorption</span></a></li>
<li class="toclevel-1"><a href="#Controlled_Trials"><span class="tocnumber">5</span> <span class="toctext">Controlled Trials</span></a></li>
<li class="toclevel-1"><a href="#Side-Effects"><span class="tocnumber">6</span> <span class="toctext">Side-Effects</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Uses" id="Uses"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/b/Ambien_CR_5ce8.html" title="Edit section: Uses">edit</a>]</span> <span class="mw-headline">Uses</span></h2>
<p><b>Ambien CR</b> is <a href="../../../f/o/o/Food_and_Drug_Administration_b75c.html" title="Food and Drug Administration">FDA</a>-approved for both short and long-term treatment of insomnia.</p>
<p><a name="Pharmacodynamics" id="Pharmacodynamics"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/b/Ambien_CR_5ce8.html" title="Edit section: Pharmacodynamics">edit</a>]</span> <span class="mw-headline">Pharmacodynamics</span></h2>
<p>Subunit modulation of the GABA receptor chloride channel macromolecular complex is hypothesized to be responsible for sedative, anticonvulsant, anxiolytic, and myorelaxant drug properties. The major modulatory site of the GABA receptor complex is located on its alpha-<sup>(a)</sup> subunit and is referred to as the benzodiazepine (BZ) receptor.</p>
<p><a href="../../../z/o/l/Zolpidem.html" title="Zolpidem">Zolpidem</a>, the active moiety of <a href="../../../z/o/l/Zolpidem.html" title="Zolpidem">zolpidem</a> tartrate, is a hypnotic agent with a chemical structure unrelated to <a href="../../../b/e/n/Benzodiazepines.html" title="Benzodiazepines">benzodiazepines</a>, <a href="../../../b/a/r/Barbiturates.html" title="Barbiturates">barbiturates</a>, pyrrolopyrazines, pyrazolopyrimidines, or other drugs with known hypnotic properties. In contrast to the <a href="../../../b/e/n/Benzodiazepines.html" title="Benzodiazepines">benzodiazepines</a>, which nonselectively bind to and activate all BZ receptor subtypes, <a href="../../../z/o/l/Zolpidem.html" title="Zolpidem">zolpidem</a> in vitro binds the BZ<sup>1</sup> receptor preferentially with a high affinity ratio of the alpha<sup>1</sup>/alpha<sup>5</sup> subunits. The BZ<sup>1</sup> receptor is found primarily on the Lamina IV of the sensorimotor cortical regions, <a href="../../../s/u/b/Substantia_nigra.html" title="Substantia nigra">substantia nigra</a> (pars reticulata), cerebellum's molecular layer, <a href="../../../o/l/f/Olfactory_bulb.html" title="Olfactory bulb">olfactory bulb</a>, ventral thalamic complex, pons, inferior colliculus, and <a href="../../../g/l/o/Globus_pallidus.html" title="Globus pallidus">globus pallidus</a>. This selective binding of <a href="../../../z/o/l/Zolpidem.html" title="Zolpidem">zolpidem</a> on the BZ<sup>1</sup> receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of <a href="../../../z/o/l/Zolpidem.html" title="Zolpidem">zolpidem</a> at hypnotic doses.</p>
<p><a name="Pharmacokinetics" id="Pharmacokinetics"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/b/Ambien_CR_5ce8.html" title="Edit section: Pharmacokinetics">edit</a>]</span> <span class="mw-headline">Pharmacokinetics</span></h2>
<p>Ambien CR exhibits biphasic absorption characteristics, which results in rapid initial absorption from the gastrointestinal tract similar to zolpidem tartrate immediate-release, then provides extended plasma concentrations beyond three hours after administration. A study in 24 healthy male subjects was conducted to compare mean zolpidem plasma concentration-time profiles obtained after single oral administration of Ambien CR (12.5 mg) and of an immediate-release formulation of zolpidem tartrate (10 mg). The terminal elimination half-life observed with Ambien CR (12.5 mg) was similar to that obtained with immediate-release zolpidem tartrate (10 mg). The mean plasma concentration time profiles for Ambien CR (12.5 mg) and for zolpidem tartrate (10 mg) are shown below:</p>
<p><a href="../../../a/m/b/Image%7EAmbien_cr2.gif_e7f5.html" class="image" title="Image:Ambien_cr2.gif"><img src="../../../upload/2/27/Ambien_cr2.gif" alt="Image:Ambien_cr2.gif" width="482" height="274" longdesc="../../../a/m/b/Image%7EAmbien_cr2.gif_e7f5.html" /></a></p>
<p><a name="Absorption" id="Absorption"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/b/Ambien_CR_5ce8.html" title="Edit section: Absorption">edit</a>]</span> <span class="mw-headline">Absorption</span></h2>
<p>Following administration of Ambien CR, administered as a single 12.5-mg dose in healthy male adult subjects, the mean peak concentration (cmax) of zolpidem was 134 ng/mL (range: 68.9 to 197 ng/ml) occurring at a median time (tmax) of 1.5 hours. The mean AUC of zolpidem was 740 ng·hr/mL (range: 295 to 1359 ng·hr/mL).</p>
<p>A food-effect study in 45 healthy volunteers compared the pharmacokinetics of Ambien CR 12.5 mg when administered while fasting or within 30 minutes after a meal. Results demonstrated that with food, mean AUC and cmax were decreased by 23% and 30%, respectively, while median tmax was increased from 2 hours to 4 hours. The half-life was not changed. These results suggest that, for faster sleep onset, Ambien CR should not be administered with or immediately after a meal.</p>
<p>Total protein binding was found to be 92.5 ± 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.</p>
<p>Ambien CR administered as a single 12.5 mg dose in healthy male adult subjects, the mean zolpidem elimination half-life was 2.8 hours (range: 1.62 to 4.05 hr).</p>
<p><a name="Controlled_Trials" id="Controlled_Trials"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/b/Ambien_CR_5ce8.html" title="Edit section: Controlled Trials">edit</a>]</span> <span class="mw-headline">Controlled Trials</span></h2>
<p>Ambien CR was evaluated in two placebo-controlled studies for the treatment of patients with chronic primary insomnia (as defined in the APA Diagnostic and Statistical Manual of Mental Disorders, DSM IV).</p>
<p>Adult outpatients (18-64 years) with primary insomnia (N=212) were evaluated in a double-blind, randomized, parallel-group, 3-week trial comparing Ambien CR 12.5 mg and placebo. Ambien CR 12.5 mg decreased wake time after sleep onset (WASO) for the first 7 hours during the first 2 nights and for the first 5 hours after 2 weeks of treatment. Ambien CR 12.5 mg was superior to placebo on objective measures (polysomnography recordings) of sleep induction (by decreasing latency to persistent sleep [LPS]) during the first 2 nights of treatment and after 2 weeks of treatment. Ambien CR 12.5 mg was also superior to placebo on the patient reported global impression regarding the aid to sleep after the first 2 nights and after 3 weeks of treatment.</p>
<p>Elderly outpatients (³ 65 years) with primary insomnia (N=205) were evaluated in a double-blind, randomized, parallel-group, 3-week trial comparing Ambien CR 6.25 mg and placebo. Ambien CR 6.25 mg decreased wake time after sleep onset (WASO) for the first 6 hours during the first 2 nights and the first 4 hours after 2 weeks of treatment. Ambien CR 6.25 mg was superior to placebo on objective measures (polysomnography recordings) of sleep induction (by decreasing latency to persistent sleep [LPS]) during the first 2 nights of treatment and after 2 weeks on treatment. Ambien CR 6.25 mg was superior to placebo on the patient reported global impression regarding the aid to sleep after the first 2 nights and after 3 weeks of treatment.</p>
<p>In both studies, in patients treated with Ambien CR, polysomnography showed increased wakefulness at the end of the night compared to placebo-treated patients.</p>
<p><a name="Side-Effects" id="Side-Effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/b/Ambien_CR_5ce8.html" title="Edit section: Side-Effects">edit</a>]</span> <span class="mw-headline">Side-Effects</span></h2>
<p>Next-day residual effects: In five clinical studies; three controlled studies in adults (18-64 years of age) administered Ambien CR 12.5 mg and two controlled studies in the elderly (³ 65 years of age) administered Ambien CR 6.25 mg or 12.5 mg, the effect of Ambien CR on vigilance, memory, or motor function were assessed using neurocognitive tests. In these studies, no significant decrease in performance was observed eight hours after a nighttime dose. In addition, no evidence of next-day residual effects were detected with Ambien CR 12.5 mg and 6.25 mg using self-ratings of sedation.</p>
<p>Next day somnolence was reported by 15% of the adult patients who received 12.5 mg Ambien CR versus 2% of the placebo group. Next day somnolence was reported by 6% of the elderly patients who received 6.25 mg Ambien CR versus 5% of the placebo group. (See Adverse Reactions.)</p>
<p>Rebound effects: Rebound insomnia, defined as a dose-dependent worsening in sleep parameters (latency, sleep efficiency, and number of awakenings) compared with baseline following discontinuation of treatment, is observed with short- and intermediate-acting hypnotics. In the two placebo-controlled studies in patients with primary insomnia, a rebound effect was only observed on the first night after abrupt discontinuation of Ambien CR. On the second night, there was no worsening compared to baseline in the Ambien CR group.</p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/b/Ambien_CR_5ce8.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<ul>
<li><a href="http://www.rxlist.com" class="external text" title="http://www.rxlist.com" rel="nofollow">rxlist.com</a></li>
</ul>

<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/m/b/Ambien_CR_5ce8.html">http://en.wikipedia.org../../../a/m/b/Ambien_CR_5ce8.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../a/n/x/Category%7EAnxiolytics_f780.html" title="Category:Anxiolytics">Anxiolytics</a></span> | <span dir='ltr'><a href="../../../h/y/p/Category%7EHypnotics_bf93.html" title="Category:Hypnotics">Hypnotics</a></span> | <span dir='ltr'><a href="../../../i/m/i/Category%7EImidazopyridines_216f.html" title="Category:Imidazopyridines">Imidazopyridines</a></span> | <span dir='ltr'><a href="../../../s/e/d/Category%7ESedatives_8eb9.html" title="Category:Sedatives">Sedatives</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/m/b/Ambien_CR_5ce8.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/m/b/Talk%7EAmbien_CR_3bff.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Ambien_CR">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 23:06, 18 March 2007 by Wikipedia user <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>. Based on work by Wikipedia user(s) <a href="../../../a/l/p/User%7EAlphaquad_7c93.html" title="User:Alphaquad">Alphaquad</a>, <a href="../../../n/i/e/User%7ENiels_Olson_0d00.html" title="User:Niels Olson">Niels Olson</a>, ChrisRBennett, <a href="../../../r/a/d/User%7ERadagast83_195a.html" title="User:Radagast83">Radagast83</a>, <a href="../../../a/v/a/User%7EAvalyn_8a13.html" title="User:Avalyn">Avalyn</a>, <a href="../../../a/l/p/User%7EAlphachimpbot_48b3.html" title="User:Alphachimpbot">Alphachimpbot</a>, <a href="../../../m/b/o/User%7EMboverload_cce2.html" title="User:Mboverload">Mboverload</a>, <a href="../../../j/o/e/User%7EJoeBot_e8e1.html" title="User:JoeBot">JoeBot</a>, <a href="../../../m/e/t/User%7EMetta_Bubble_dc7b.html" title="User:Metta Bubble">Metta Bubble</a>, <a href="../../../p/r/i/User%7EPrisonnet_e729.html" title="User:Prisonnet">Prisonnet</a>, <a href="../../../s/i/m/User%7ESimonP_1010.html" title="User:SimonP">SimonP</a> and <a href="../../../k/b/i/User%7EKBi_bd39.html" title="User:KBi">KBi</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
